Ofev

nintedanib · Boehringer Ingelheim International GmbH
AUTHORISED IN THE EU

What Ofev is used for

Ofev is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Ofev
Active substance
nintedanib
Disease area
Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis; Scleroderma, Systemic
Medicine group
Antineoplastic agents
ATC code
L01EX09
Marketing authorisation holder
Boehringer Ingelheim International GmbH
Authorised in the EU since
2015

Official information

In India

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Ofev used for?

Ofev is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

What is the active substance in Ofev?

Ofev contains nintedanib.

Who makes Ofev?

The EU marketing authorisation holder is Boehringer Ingelheim International GmbH.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.